Featuring interviews with Drs Corey J Langer, Robert Haddad, David I Rosenthal and Everett E Vokes. (Text and Audio Content)
OVERVIEW OF ACTIVITY
Approximately 47,560 new cases of head and neck (H&N) cancer are estimated to occur in the United States during 2008, accounting for three percent of all types of cancer, and more than 11,000 patients will die from the disease. Treatment for patients with H&N cancer is complex and requires a multidisciplinary team of individuals with expertise in the special care needs of these patients. The site and extent of disease and pathologic findings dictate the appropriate surgical approach, radiation field, dose and fractionation and indications for chemotherapy and/or biologic therapy. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists and radiation oncologists must be well informed of these advances. To bridge the gap between research and patient care, Head and Neck Cancer Update features one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists these physicians with the formulation of up-to-date clinical management strategies.
Featuring interviews with Drs Corey J Langer, Robert Haddad, David I Rosenthal and Everett E Vokes. (Text and Audio Content)